Autologous Hematopoietic Stem Cell Transplantation for Early Onset Type 1 Diabetes

• Status: Unknown status
• Trial end date: 2016-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a phase II trial in individuals who have been diagnosed with type 1 diabetes within the previous 6 months. The study is evaluating whether stem cell transplantation is safe when chemotherapy and immunotherapy are used in combination and if it has immune resetting effect that may halt the immune attack to pancreas islets and thus preserve the body's own insulin production.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Jiao Tong University School of Medicine
• Treatments: Insulin; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 1 diabetes mellitus diagnosed by clinical/metabolic parameters and positive anti-GAD antibody

• Less than 6 months from diagnosis

Exclusion Criteria:

• Previous diabetic ketoacidosis

• Pregnancy

• Severe psychiatric disorder

• Severe organic impairment (renal, hepatic, cardiac, pulmonary)

• Active infectious disease

• Previous or present neoplastic disease